Unlock LNP potential with enhanced clinical translatability at the 3rd Lipid Nanoparticles Development Summit Europe (24-26 September, Berlin, Germany), the leading dedicated LNP f
2023 is set to be a landmark year for lipid-based delivery technology development and the 2nd Next-Generation Lipid-Based Nanoparticle Delivery Summit re
Yesterday, the biotechnology company Capstan Therapeutics launched with $165 million in seed and Series A funding for it to build on its foundational insights into precision in vivo